// App-Quantinova.ai

399 : Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Researchers

Presenter

  • Janine Stutterheim

Principal Investigators

  • Paola De Lorenzo

  • Julia Alten

  • Philip Ancliff

  • Andishe Attarbaschi

  • Benoit Brethon

  • Andrea Biondi

  • Myriam Campbell

  • Giovanni Cazzaniga

  • Gabriele Escherich

  • Alina Ferster

  • Rishi Sury Kotecha

  • Birgitte Lausen

  • Chi Kong Li

  • Luca Lo Nigro

  • Franco Locatelli

  • Rolf Marschalek

  • Martin Schrappe

  • Jan Stary

  • Ajay Vora

  • Jan Zuna

  • Vincent H.J. Van Der Velden

  • Tomasz Szczepanski

  • Maria Grazia Valsecchi

  • Rob Pieters

Medical Centers

  • Princess Maxima Center, Utrecht, Netherlands

  • Princess Maxima Center for Pediatric Oncology, Netherlands

  • University of Milano-Bicocca, Monza, Italy

  • Dept. of Pediatrics, UKSH, Kiel, DEU

  • Department of Haematology, Great Ormond Street Hospital, London, UK, London, GBR

  • St. Anna Children s Hospital, Vienna, Austria

  • BFM-A – Berlin-Frankfurt-Münster Austria, Vienna, Austria

  • FRALLE - French Acute Lymphoblastic Leukemia Study Group, Paris, France

  • Dept. Pediatrics, University of Milano-Bicocca, Fondazione MBBM/San Gerardo Hospital, Monza, Italy

  • AIEOP - Associazione Italiana Ematologia Oncologia Pediatrica, Monza, Italy

  • Hospital Roberto del Rio Santiago, Chilean National Pediatric Oncology Group, PINDA., Santiago, Chile

  • Tettamanti Research Center, Department of Pediatrics, University of Milano-Bicocca, San Gerardo Hospital/Fondazione MBBM, Monza, Italy

  • Department of Pediatric Hematology and Oncology, University Medical Center Eppendorf, Hamburg, Germany

  • German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia, Hamburg, Germany

  • Pediatric Hematology, Hopital Universitaire des Enfants Reine Fabiola, Universite Libre de Bruxelles, Brussels, Belgium

  • Telethon Kids Institute, University of Western Australia, Perth, Australia

  • ANZCHOG - Australia New Zealand Children Oncology Group, Perth, Australia

  • NOPHO – Nordic Society of Pediatric Hematology/Oncology, Copenhagen, Denmark

  • Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark

  • Department of Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong

  • Head of Cytogenetic-Cytofluorimetric-Molecular Biology Lab - Azienda Policlinico OVE - Center of Pediatric Hematology Oncology, Catania, Italy

  • IRCCS Ospedale Pediatrico Bambino Gesù, Sapienza,University of Rome,Rome,Italie

  • Institute of Pharmaceutical Technology, Goethe-University, Frankfurt Am Main, Germany

  • BFM-G - Berlin-Frankfurt-Münster Group Germany, Kiel, Germany

  • CPH- Czech Working Group for Pediatric Hematology, Prague, Czech Republic

  • Great Ormond Street Hospital, London, United Kingdom

  • UKCCSG - United Kingdom Children Cancer Study Group, London, United Kingdom

  • Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic

  • Department of Immunology, Erasmus University Medical Center, Rotterdam, NLD

  • Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia, Katowice, Poland

  • PPLLSG - Polish Pediatric Leukemia/Lymphoma Study Group, Zabrze, Poland

  • University of Milano-Bicocca, Monza, Italy

  • Princess Maxima Center for Pediatric Oncology, Netherlands

Locations

  • Netherlands

  • Italy

  • Austria

  • France

  • Chile

  • Germany

  • Belgium

  • Australia

  • Denmark

  • Hong Kong

  • Czech Republic

  • United Kingdom

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • T-cell receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved